Expertise in
1
conditions

Khurum H. Khan

London, ENG, GB 
Expertise in
1
conditions
London, ENG, GB 

Overview

Khurum Khan practices practicing medicine in London, United Kingdom.

Khan is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Colorectal Cancer, COVID-19, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatic Ductal Adenocarcinoma.

They are actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 2 clinical trials.

Locations

London, ENG, United Kingdom
Other Locations
Sutton Upon Derwent, ENG SM25PT, United Kingdom
Marsden, ENG, United Kingdom
Belfast, NIR, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
View 1 Less Clinical Trial

64 Total Publications

Apparent diffusion coefficient and kurtosis parameters show early response to anti-angiogenic therapy in patients with colorectal liver metastases.
Apparent diffusion coefficient and kurtosis parameters show early response to anti-angiogenic therapy in patients with colorectal liver metastases.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: March 10, 2026

Frequently Asked Questions about Khurum H. Khan

Is Khurum H. Khan a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Khurum H. Khan is classified as an Advanced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Khurum H. Khan participate in research or clinical trials?

Yes. Khurum H. Khan has published 64 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Khurum H. Khan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Khan's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile